A personalized mRNA shot is helping melanoma patients stay cancer-free longer

In a Phase 3 trial, an mRNA vaccine custom-built from each patient's own tumor cut melanoma recurrence nearly in half when paired with the immunotherapy drug Keytruda. The vaccine teaches the immune system to recognize the unique fingerprint of that person's cancer. After decades of treating melanoma the same way for everyone, medicine is finally getting personal.